B. Riley Raises Lam Research Price Target to $375

Analyst: Craig Ellis 1 min read Reproduced verbatim
Rating
Buy
Target
$375
from $350 (+7%)
Outcome
Reached
on June 15, 2026
B Riley and Lam Research logos

What the analyst said

B.Riley analyst Craig Ellis raised the price target on Lam Research (NASDAQ: LRCX) to $375.00 (from $350.00) while maintaining a Buy rating.

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Where the price stands

LRCX trades at $185. The 9 analysts who set a target in the last 3 months range from $290 to $400, with a median of $350. This $375 target is 7% above the median.

Since the note LRCX has moved −37% (from $296). 12-month window: day 177 of 365, closes on May 12, 2027.

Track record

This call✓ Target reached on June 15, 2026, 34 days after the note.

Firm track recordToo early to score B Riley: price targets are 12-month calls and fewer than 5 of its targets are a year old. 4 of its 16 open targets have already been reached. How we score

B Riley on Lam Research

B Riley price targets on Lam Research

4 calls from May 12, 2026 to October 19, 2026. The target went from $375 to $338 (−10%). The rating stayed Buy.

B Riley targetLRCX share price
  1. October 19, 2026Target cut from $390 (−13%)Buy$338
  2. October 1, 2026Target raised from $350 (+11%)Buy$390
  3. July 30, 2026Target cut from $375 (−7%)Buy$350
  4. May 12, 2026 This noteEarliest call shownBuy$375
Share
Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.